$GEVO

Bloom Paul D sold $133K of GEVO

Bloom Paul D (CEO) sold 75,735 shares of Gevo, Inc. (GEVO) at $1.76 ($0.13M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bloom Paul D
Published May 29, 2026, 9:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GEVO
Neutral
medium confidence
Mentioned
$GEVO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEVONeutralLow
01

Why it matters

The disclosure can influence short-term sentiment, but 10b5-1 plans generally indicate the trades were scheduled in advance, lowering the probability of new, material negative information.

02

Market read

A single insider sale under a 10b5-1 plan is typically a low-signal event for price, unless paired with other fundamental news.

03

What to watch

Traders should check whether there were concurrent insider buys/sales, changes in guidance, or volume/price reaction around the May 27 execution date—none are provided here.

Relevance 6/10Novelty 6/10Timing: Filed May 29; sale executed May 27 under a 10b5-1 plan.

Background

This is an SEC Form 4 insider transaction: CEO Paul D. Bloom sold shares in an open-market transaction under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$GEVONeutralMedium confidence
Context

CEO Paul D. Bloom sold 75,735 shares in an open-market transaction disclosed via SEC Form 4 on May 27, 2026.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other catalysts.

Evidence & confidence

The filing provides a specific sale datapoint, but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically dampens the market’s inference of new negative information.

Market effects

For speculative energy/renewables names, insider selling can briefly pressure sentiment, but this is company-specific and not a sector reset.

No clear regional spillover indicated by the filing alone.

Minimal; this is a single-company insider transaction disclosure.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a change in fundamentals.

Key entities

  • Gevo, Inc.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • Paul D. Bloom

    CEO and officer/director who sold 75,735 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GEVOMedAI 8/10

Gevo (GEVO) Q2 2026 Earnings Call Transcript

Gevo (GEVO) reported Q2 2026 revenue of $47 million, up 7% year over year, and non-GAAP adjusted EBITDA of $11 million. Full-year 2026 adjusted EBITDA guidance is now above $60 million. The company targets $70 million of 45Z tax credit monetization in 2026 and recorded a $176 million noncash impairment tied to exiting its ATJ-60 project.

$GEVOHigh

Gevo, Inc. (GEVO): Results of Operations and Financial Condition

Gevo, Inc. (GEVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gevo Reports Second Quarter Results and Raises Financial Expectations for Full-Year 2026 ENGLEWOOD, Colo. – August 6, 2026 – Gevo, Inc. (NASDAQ: GEVO), a leader in renewable fuels, chemicals and carbon management, today announced its financial results for the second

$GEVOMedAI 8/10

Why Is Gevo (GEVO) Stock Rocketing Higher Today

Gevo (NASDAQ: GEVO) shares rose about 7.5% after the company said it expects 2026 non-GAAP Adjusted EBITDA to be more than double prior estimates. Gevo attributed the upgrade to new carbon pathways, higher production, and cost reductions, and it announced Todd Werpy, Ph.D., joining its board. The stock is volatile and trades at $1.68.